NEW YORK, June 4, 2026, 08:05 EDT
- Averin Capital Class A shares were last at $9.93, off 5 cents, down about 0.5%.
- Nasdaq’s normal session runs from 9:30 a.m. to 4 p.m. ET. June 4 isn’t shown as a 2026 market holiday.
- The SPAC’s most recent SEC filing put Akiko Moni Miyashita on the board, but didn’t name a merger target.
Averin Capital Acquisition Corp.’s Class A shares closed at $9.93 on Wednesday, about 1% under the SPAC’s most recent redemption value of $10.03 a share. That redemption value is what public holders could get in certain votes or if the SPAC liquidates. Averin reported $284.85 million in trust as of March 31, according to its filing.
SPACs, the listed cash shells searching for a business to buy, are seeing just a slight discount and that’s the key story at the moment. Ahead of any deal news, investors are focused on trust cash, trading liquidity, and how much time is left on the SPAC’s deal clock, not earnings.
Nasdaq says Thursday will run on regular trading hours from 9:30 a.m. to 4 p.m. Eastern, with pre-market access as usual. Its 2026 holiday list puts Juneteenth, June 19, as the next full day off.
S&P 500 and Nasdaq 100 futures traded weaker in early moves. Nasdaq 100 futures dropped 1.2% at 6:47 a.m. ET, according to Reuters, after Broadcom’s earnings put pressure on chip names. Dan Coatsworth, head of markets at AJ Bell, said Broadcom’s quarter proved that “meeting and even slightly beating forecasts is not enough” if expectations are high. Reuters
Averin isn’t directly affected here. But it could still be relevant, since Averin has told investors it’s looking for targets where tech meets health. Those parts of the market are known for fast changes in valuation and funding mood.
Averin wrapped up a $250 million IPO in February, moving 25 million units for $10 apiece. Each unit was made up of one Class A ordinary share and a sixth of a redeemable warrant. Investors get to exercise each whole warrant at $11.50 per share.
Averin’s IPO got a boost when Deutsche Bank Securities, acting as sole book-runner, took up part of its over-allotment. That saw another 3,386,008 units sold at $10 apiece, bringing total gross proceeds from the offering to $283.86 million.
From April 10, investors could split their IPO units, with Class A shares now trading as ACAA and warrants as ACAAW. Units that haven’t been split still trade as ACAAU. The company said it won’t issue fractional warrants.
Averin’s latest Form 8-K was about governance. The company said its board put Akiko Moni Miyashita on as director, effective May 28. The May 29 filing pointed to Miyashita’s work in strategy, M&A, AI, healthcare, life sciences, technology and global markets.
Averin traded near other SPACs that stick close to $10. Google Finance’s related-stock panel listed Armada Acquisition Corp III at $9.95 and Art Technology Acquisition Corp at $9.93. These stocks tend not to budge much without a clear deal on deck.
Averin hasn’t picked a business-combination target yet, according to its prospectus, which also flagged that more competition among SPACs could drive up costs or make good targets harder to find. The SPAC has a 24-month window for an initial deal, with an option to stretch that to 27 months if it signs a definitive agreement by the two-year mark. The stock could get more volatile if things change.
Averin could see its discount narrow if it sets a strong target. But the stock may hang around cash value or dip below if the deal falls flat, if redemptions go up, or if tech-health names drop with the Nasdaq. Warrants would likely feel more pressure in that case.
